Ultragenyx Pharmaceutical (RARE) News Today $40.00 -0.85 (-2.08%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside PotentialJanuary 17 at 6:33 PM | msn.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 17 at 4:30 PM | globenewswire.comFY2024 EPS Estimates for RARE Raised by Cantor FitzgeraldUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2024 earnings estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now forJanuary 17 at 6:40 AM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Hennion & Walsh Asset Management Inc.Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 19.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 63,January 17 at 5:34 AM | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7% - Should You Sell?Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7% - Here's What HappenedJanuary 16 at 10:21 PM | marketbeat.comEvercore ISI Remains a Buy on Ultragenyx Pharmaceutical (RARE)January 16 at 9:57 PM | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 9.1% - Here's What HappenedUltragenyx Pharmaceutical (NASDAQ:RARE) Trading 9.1% Higher - Time to Buy?January 15 at 12:49 PM | marketbeat.comPositive Outlook on Ultragenyx Pharmaceuticals Driven by Strong Financials and Promising PipelineJanuary 15 at 9:05 AM | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $140.00 at Piper SandlerJanuary 15 at 2:09 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 5.7% - Time to Sell?Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7% - Should You Sell?January 14, 2025 | marketbeat.comTD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)January 13, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical (RARE) Receives a Hold from WedbushJanuary 13, 2025 | markets.businessinsider.comUltragenyx Pharmaceutical: Strong Revenue Forecasts and Pipeline Advancements Justify Buy RatingJanuary 13, 2025 | markets.businessinsider.comStrong Buy Recommendation for Ultragenyx Pharmaceutical Based on Robust Performance and Promising Clinical PipelineJanuary 13, 2025 | markets.businessinsider.comPiper Sandler Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) StockPiper Sandler upped their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday.January 13, 2025 | marketbeat.comUltragenyx Pharmaceutical's (RARE) Neutral Rating Reaffirmed at WedbushWedbush restated a "neutral" rating and issued a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday.January 13, 2025 | marketbeat.comUltragenyx Pharma Projects FY24 Revenue To Surpass Its ExpectationsJanuary 12, 2025 | markets.businessinsider.comUltragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 MilestonesJanuary 12, 2025 | globenewswire.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $88.46January 12, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and twelve haveJanuary 9, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading 7.2% Higher - Time to Buy?Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading 7.2% Higher - Still a Buy?January 7, 2025 | marketbeat.comBank of America Securities Remains a Buy on Ultragenyx Pharmaceutical (RARE)January 7, 2025 | markets.businessinsider.comUltragenyx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comUltragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorderJanuary 6, 2025 | finance.yahoo.comUltragenyx Pharmaceutical Inc. Announces Extended European Approval for Evkeeza® in Young Children with Homozygous Familial HypercholesterolemiaJanuary 6, 2025 | quiverquant.comEuropean Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)January 6, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Principal Financial Group Inc.Principal Financial Group Inc. lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 740.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,440 shares of the bioJanuary 3, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $495,231.21 in StockJanuary 1, 2025 | insidertrades.comInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells 11,727 Shares of StockUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CEO Emil D. Kakkis sold 11,727 shares of the firm's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the transaction, the chief executive officer now directly owns 2,183,985 shares of the company's stock, valued at $92,229,686.55. The trade was a 0.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.December 31, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)HC Wainwright reiterated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday.December 24, 2024 | marketbeat.comBarclays PLC Sells 157,367 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Barclays PLC lessened its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 66.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,546 shares of the biopharmaceutical company's sDecember 22, 2024 | marketbeat.comFranklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Franklin Resources Inc. lessened its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 25.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 218,903 shares of the biophDecember 21, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc.: Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman SyndromeDecember 20, 2024 | finanznachrichten.deWells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)December 20, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISIDecember 20, 2024 | markets.businessinsider.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 20, 2024 | globenewswire.comUltragenyx Pharmaceutical (NASDAQ:RARE) Given New $88.00 Price Target at Wells Fargo & CompanyWells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research note on Friday.December 20, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 4.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,571,081 shares of the biopharmaceutical company's stock afterDecember 20, 2024 | marketbeat.comNHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)December 20, 2024 | globenewswire.comUltragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman SyndromeDecember 19, 2024 | globenewswire.comUltragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)December 19, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and twelve have aDecember 15, 2024 | marketbeat.comState Street Corp Lowers Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)State Street Corp lowered its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,664,077 shares of the biopharmaceutical coDecember 14, 2024 | marketbeat.comY Intercept Hong Kong Ltd Buys 12,617 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Y Intercept Hong Kong Ltd raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 193.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,151 shares of the biopharmacDecember 13, 2024 | marketbeat.comJanus Henderson Group PLC Has $2.03 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Janus Henderson Group PLC trimmed its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 49.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 36,543 shares of the biopharmaceutical company's stock after selling 35,200 shares during theDecember 13, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $413,650.00 in StockDecember 12, 2024 | insidertrades.comTD Cowen Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)December 11, 2024 | markets.businessinsider.comFrazier Life Sciences Management L.P. Has $35.20 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Frazier Life Sciences Management L.P. lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 49.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 633,715 shares of the biopharDecember 10, 2024 | marketbeat.comWellington Management Group LLP Lowers Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Wellington Management Group LLP trimmed its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,165,424 shares of theDecember 9, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Decreased by BNP Paribas Financial MarketsBNP Paribas Financial Markets reduced its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 57.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,831 sDecember 9, 2024 | marketbeat.com Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼0.670.64▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼247▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Viatris News Intra-Cellular Therapies News Summit Therapeutics News Moderna News Dr. Reddy's Laboratories News Sarepta Therapeutics News Catalent News Qiagen News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts